Kangyuan Biotech-B (06922) announced that it will reach a distribution agreement with Bocok International Medical Trade (Shanghai) Co., Ltd., effective July 1, 2024, regarding respiratory intervention products in mainland China.
Kangyuan Biotech-B (06922) announced that it will reach a distribution agreement with Bocok International Medical Trade (Shanghai) Co., Ltd., effective July 1, 2024, regarding respiratory intervention products in mainland China.
Bocok International Medical Trade (Shanghai) Co., Ltd. is a subsidiary of Boston Scientific Corporation (a publicly traded company on the New York Stock Exchange (stock code: BSX)) in China. Boston Scientific is a global leader in medical technology, driving innovation in patient-care solutions and lowering healthcare costs with a broad range of high-performance products. Its device and therapy combinations help diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions.
According to the distribution agreement, the group confirmed its strategic partnership with Bocok International Medical Trade (Shanghai) Co., Ltd. in the field of respiratory intervention products in mainland China.The group will act as the market promotion partner and exclusive sales agent for Bocok International Medical Trade (Shanghai) Co., Ltd.'s respiratory intervention products in mainland China, combined with Bocok International Medical Trade (Shanghai) Co., Ltd.'s resources and support to promote the commercialization of these products in mainland China.
The Board of Directors believes that the distribution agreement provides valuable opportunities for the contracting parties to establish strategic cooperation, and lays a solid foundation for creating synergies in the field of respiratory intervention by utilizing their respective business layout, professional knowledge, and resources. Moreover, the agreement facilitates the integration of market resources and layout planning in advance for the group's subsequent respiratory intervention product launches. Therefore, the Board of Directors believes that signing the distribution agreement is in the overall interests of the company and its shareholders.